Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 43%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is facing challenges related to competition in the market of generic/biosimilar drugs, which could significantly impact their earnings in the near future. However, their focus on innovation and development of new products, particularly in their immuno-oncology platform with Keytruda, is expected to drive growth in the long term. With strong financials and a diverse portfolio including vaccines and animal health products, Merck is well positioned for continued success in the pharmaceutical industry.

Bears say

Merck & Co is expected to have a weak quarter and year as they face numerous challenges with their Keytruda drug and other pipeline assets, including uncertainty surrounding upcoming data releases. With a recent acquisition and a weak outlook, its valuation has seen little movement and the company has acknowledged risks ranging from climate change to regulatory pressures. Despite low expectations, there is the potential for beats on top and bottom-line results given management's track record and conservative guidance approach.

Merck (MRK) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 43% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 21 analysts, Merck (MRK) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $140.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $140.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.